How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Syndromic Multiplex Test Market
- By Product Type: Respiratory Panels, Gastrointestinal Panels, Sexually Transmitted Infection (STI) Panels, Central Nervous System (CNS) Panels, Blood Culture Identification Panels
- By End User: Hospitals, Diagnostic Laboratories, Academic and Research Institutes, Point-of-Care Testing Centers, Reference Laboratories
- By Technology: Polymerase Chain Reaction (PCR), Microarray, Next-Generation Sequencing (NGS), Isothermal Amplification, Multiplexed Immunoassays
- By Application: Infectious Disease Diagnosis, Outbreak Surveillance, Antimicrobial Stewardship, Hospital-Acquired Infection Detection, Biodefense and Biosecurity
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Respiratory Panels leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 284 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Syndromic Multiplex Test Market report
A complete, evidence-based study - 11 chapters and 119 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
End User 5
Technology 5
Application 5
Companies profiled
bioMérieux
Qiagen
Luminex Corporation
Hologic Inc.
Abbott Laboratories
Thermo Fisher Scientific
GenMark Diagnostics
BD (Becton
Dickinson and Company)
Roche Diagnostics
Cepheid (a Danaher company)
Fast Track Diagnostics (a Siemens Healthineers company)
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →bioMérieux
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Qiagen
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Luminex Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →GenMark Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →BD (Becton
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dickinson and Company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Roche Diagnostics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Cepheid (a Danaher company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Fast Track Diagnostics (a Siemens Healthineers company)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Seegene Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Mobidiag (a Hologic company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Fujirebio
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Altona Diagnostics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$4,345M by 2033 · 3.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Respiratory Panels42.1
- Gastrointestinal Panels12.7
- Sexually Transmitted Infection (STI) Panels15.8
- Central Nervous System (CNS) Panels9.7
- Blood Culture Identification Panels19.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,056M → $1,388M · 3.5%
Europe$736.2M → $922.5M · 2.9%
Asia Pacific$672.2M → $846.0M · 2.9%
Latin America$416.1M → $546.2M · 3.5%
Middle East and Africa$320.1M → $433.3M · 3.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.852026
3.852027
3.882028
3.882029
3.892030
3.902031
3.912032
3.932033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- bioMérieux17.3
- Qiagen22.6
- Luminex Corporation3.7
- Hologic Inc.9.5
- Abbott Laboratories8.8
- Thermo Fisher Scientific10.1
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type13.7%
End User31.5%
Technology19.7%
Application35.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.6
- Europe22.3
- Asia Pacific20.5
- Latin America13.2
- Middle East and Africa10.5
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| bioMérieux | 75 | 87 | 78 | 90 | 94 | 82 | 84 |
| Qiagen | 92 | 86 | 81 | 73 | 69 | 72 | 79 |
| Luminex Corporation | 65 | 69 | 82 | 74 | 69 | 63 | 70 |
| Hologic Inc. | 61 | 76 | 67 | 66 | 74 | 61 | 68 |
| Abbott Laboratories | 58 | 54 | 75 | 75 | 69 | 75 | 68 |
| Thermo Fisher Scientific | 67 | 47 | 46 | 66 | 66 | 53 | 58 |
| GenMark Diagnostics | 53 | 47 | 50 | 64 | 59 | 61 | 56 |
| BD (Becton | 52 | 55 | 47 | 35 | 47 | 50 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- bioMérieux
- Qiagen
- Luminex Corporation
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| bioMérieux | − | ◐ | ✓ | ◐ | ✓ | ✓ |
| Qiagen | ✓ | ◐ | ◐ | ◐ | ✓ | ✓ |
| Luminex Corporation | ◐ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Hologic Inc. | − | ◐ | ◐ | − | ✓ | ◐ |
| Abbott Laboratories | − | ◐ | ✓ | ◐ | ◐ | ✓ |
| Thermo Fisher Scientific | ◐ | − | ◐ | ◐ | ◐ | − |
| GenMark Diagnostics | − | − | − | ◐ | ◐ | ◐ |
| BD (Becton | ◐ | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1bioMérieux84
2Qiagen79
3Luminex Corporation70
4Hologic Inc.68
5Abbott Laboratories68
6Thermo Fisher Scientific58
7GenMark Diagnostics56
8BD (Becton48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
bioMérieuxQiagen
Challenger3
Strong scale, closing on the leaders.
Luminex CorporationHologic Inc.Abbott Laboratories
Contender1
Focused players with pockets of strength.
Thermo Fisher Scientific
Niche2
Specialists in a single segment or region.
GenMark DiagnosticsBD (Becton
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Product Type in North America, then scale across Syndromic Multiplex Test Market — a $240M beachhead inside a $4.23B market.
Beachhead (SOM)$240Mobtainable near-term
Serviceable (SAM)$1.51Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Respiratory Panels
Best fit — highest urgency & budget in Product Type.
Economic buyer77 fit
Gastrointestinal Panels
Strong fit — clear ROI and a fast path to value.
End user66 fit
Sexually Transmitted Infection (STI) Panels
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add End User & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Technology
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve20%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Syndromic Multiplex Test Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified25%
Evaluation14%
Closed-won7%
$21.7KCAC
$113KLTV
5.2:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Syndromic Multiplex Test Market is a high-growth opportunity — $9.45B by 2033, compounding at 11.4%.
TAM · 2025$3.98Btoday
TAM · 2033$9.45Bforecast
CAGR11.4%2027–2033
Cumulative$57.4Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.45BTotal addressable market
SAM$3.27BServiceable available market
SOM$668MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.45BLarge & growingTAM by 2033 at 11.4% CAGR
$3.27BServiceable nowreachable with today’s model
$668MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.37BBear7.4% CAGR
$9.45BBase11.4% CAGR
$12.1BBull15.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & End User optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Syndromic Multiplex Test Market — a $12.4B market by 2033. Plan: grow share from 9.4% to 16.4%.
Market size · 2033$12.4Btotal addressable
Market CAGR11.0%2027–2033
Target share16.4%from 9.4% today
Revenue ambition$2.03Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.4% | 16.4% | On track |
| Revenue | $1.26B | $2.03B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 36.0% | 40.1% | On track |
| Customer retention | 86.4% | 95.0% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build End User capability
A defensible second engine — invest in End User to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch End User
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $264M capacity & capability investment
- Greenlight bolt-on M&A in End User
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Syndromic Multiplex Test Market conversation — a $7.55B market you can size, segment and defend in minutes.
Market size · 2033$7.55Btotal opportunity
Growth5.6%CAGR to 2033
Addressable buyers989+accounts in scope
Typical ROI5.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.7×return on cost, year one
< 3 mopayback period
$75K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
bioMérieuxQiagenLuminex CorporationHologic Inc.Abbott LaboratoriesThermo Fisher ScientificGenMark DiagnosticsBD (Becton+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Syndromic Multiplex Test Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Syndromic Multiplex Test Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Syndromes Progressive Ataxia Weakness Disorders Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportSyndrome Progressive Ataxia Weakness Disorder Treatment Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportSynchronous Teledentistry Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportSynchronized Intermittent Mandatory Ventilation Ventilator Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportSyn-Bio Technology Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportSynaptotagmin-1 Antibody Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportSynaptophysin Monoclonal Antibody Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportSynaptophysin Antibody Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportSynanthrin Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportSwollen Gum Treatment Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportSwivel Bath Seat Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportSwitch Smoke Evacuation Pencil Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.